Context Therapeutics (CNTX) Net Cash Flow (2020 - 2026)
Context Therapeutics (CNTX) posted Net Cash Flow of -$11.5 million for Q1 2026, down 4.79% sequentially from -$10.9 million in Q4 2025, and down 125.83% YoY from $44.4 million in Q1 2025.
Context Therapeutics (CNTX) Net Cash Flow (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$11.5 million in Q1 2026.
- Quarterly Net Cash Flow fell 125.83% year-over-year to -$11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.8 million (down 143.93% YoY) and the FY2025 annual result came in at -$28.4 million, down 135.55% from the prior year.
- Net Cash Flow fell to -$11.5 million in Q1 2026 per CNTX's latest filing, from -$10.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $91.4 million in Q2 2024 and troughed at -$16.7 million in Q3 2024.
- A 5-year average of $284882.9 and a median of -$4.6 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 637.51% in 2022, then jumped 2074.64% in 2024.
- Over 5 years, Net Cash Flow stood at -$3.9 million in 2022, then sank by 83.91% to -$7.2 million in 2023, then jumped by 233.22% to $9.6 million in 2024, then sank by 213.65% to -$10.9 million in 2025, then declined by 4.79% to -$11.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$11.5 million, -$10.9 million, and -$6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -11.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.54 Mn |
| Jun 30, 2026 | -11.54 Mn |
| Mar 31, 2026 | -11.47 Mn |
| Mar 31, 2026 | -11.47 Mn |
| Dec 31, 2025 | -10.94 Mn |
| Dec 31, 2025 | -10.94 Mn |
| Sep 30, 2025 | -6.58 Mn |
| Sep 30, 2025 | -6.58 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Mar 31, 2025 | -5.08 Mn |
| Mar 31, 2025 | -5.08 Mn |
| Dec 31, 2024 | 9.63 Mn |
| Dec 31, 2024 | 9.63 Mn |
| Sep 30, 2024 | -16.74 Mn |
| Sep 30, 2024 | -16.74 Mn |
| Jun 30, 2024 | 91.45 Mn |
| Jun 30, 2024 | 91.45 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Mar 31, 2024 | -4.36 Mn |